In simple terms, viruses like SARS-CoV-2 can’t replicate independently, so they hijack the host cell, replicate within it and then spread throughout the body.
A Clearway Global’s client has discovered that an existing safe drug, can prevent the host cell from transporting viral components. In contrast to existing drugs that block the virus from replicating after infection, This drug candidate has the potential to prevent cellular infection.
We have worked with the inventor, a brilliant academic researcher, to organize a new company, staff it and fund the development of this possible ground-breaking treatment of Covid-19. Our first human clinical program showed a 90% success rate in treating active Covid-19 patients. The US FDA has been made aware of the results and additional clinical trials are planned to begin immediately.